KIT and gastrointestinal stromal tumor: Imatinib was firstly compared with best supportive care (BSC) or historical controls in unresectable and/or metastatic, KIT-positive GIST in three studies (29–31), and was associated with an increase in costs and QALYs compared to BSC in all studies.